Charles River Laboratories International (CRL) Cuts Guidance, Is It Still Undervalued?

Charles River Laboratories International (CRL) recently cut its 2026 GAAP earnings guidance and reported a quarterly net loss, despite strong recent share price momentum. While a narrative based on primate supply constraints suggests the stock is 14.7% undervalued, another model using discounted cash flow indicates it is significantly overvalued. Investors are advised to conduct their own analysis given these conflicting valuations.